Kenyon C J, Saccoccio N A, Morris D J
Endocrinology. 1984 Aug;115(2):535-7. doi: 10.1210/endo-115-2-535.
Antinatriuretic and kaliuretic activities of 19-oxo-deoxycorticosterone (19-oxo-DOC) were measured in male adrenalectomized rats and compared with those of aldosterone. No significant effects of 19-oxo-DOC or aldosterone were observed in the lag period (i.e. the first hour post injection). In the subsequent 2 h, rats injected with 25 micrograms 19-oxo-DOC excreted less than half the sodium and more than twice the potassium compared to rats injected with vehicle alone. Overall mineralocorticoid activity (based on changes in urinary Na+/K+), antinatriuretic activity (based on changes in urinary Na+/creatinine) and kaliuretic activity (based on changes in urinary K+/creatinine) of 19-oxo-DOC were all in the range of 1:100th-1:200th that of aldosterone. These results are not in agreement with a recent report suggesting that 19-oxo-DOC possesses antinatriuretic activity but no kaliuretic activity.
在雄性肾上腺切除大鼠中测定了19-氧代脱氧皮质酮（19-oxo-DOC）的抗利尿钠和促尿钾活性，并与醛固酮的活性进行了比较。在滞后阶段（即注射后第一小时）未观察到19-oxo-DOC或醛固酮有显著作用。在随后的2小时内，与仅注射赋形剂的大鼠相比，注射25微克19-oxo-DOC的大鼠排泄的钠不到一半，而钾则是两倍多。19-oxo-DOC的总体盐皮质激素活性（基于尿Na+/K+的变化）、抗利尿钠活性（基于尿Na+/肌酐的变化）和促尿钾活性（基于尿K+/肌酐的变化）均在醛固酮的1/100至1/200范围内。这些结果与最近一份报告不一致，该报告表明19-oxo-DOC具有抗利尿钠活性但无促尿钾活性。
